Lionheart Health and ElectroMedical Technologies have formed a strategic joint venture targeting significant improvements in wound healing technologies, with a primary focus on preventing limb amputations and enhancing patient treatment outcomes.
The partnership combines Lionheart Health's patented bioelectric signaling software with ElectroMedical Technologies' advanced device platform. Initial pilot studies have demonstrated promising results, with over 90% of patients with non-healing wounds avoiding amputation across clinical trials in the Czech Republic, Mexico, and the United States.
The joint venture plans to launch comprehensive clinical studies exploring multiple treatment protocols, including bioelectric stimulation, enhanced protein regeneration techniques, membrane grafts, and stem cell interventions. These studies aim to accelerate wound healing and provide more effective treatment options for patients with complex wound management challenges.
With approximately 185,000 amputations occurring annually in the United States, primarily related to non-healing wounds, this collaboration seeks to reduce these numbers by more than 50% within ten years. The companies will receive a 7% gross sales royalty on patient services through planned licensing of their innovative wound care technology.
The partnership leverages significant intellectual property, with Lionheart Health holding over 500 patent claims related to bioelectric protein expressions and tissue regeneration, and ElectroMedical Technologies bringing 18 years of experience in electrical stimulation device development.
By integrating advanced bioelectric healing technologies, this joint venture represents a potentially transformative approach to wound care, offering hope for patients facing critical wound healing challenges and potentially reducing long-term healthcare costs.
